TechnipFMC plc: TechnipFMC Announces Fourth Quarter 2020 Results
All segments achieved financial guidance
Total Company inbound orders of $10.1 billion; Subsea orders of $4 billion
Resilient backlog of $21.4 billion; Subsea backlog of $6.9 billion
Fourth quarter 2020
Includes total after-tax charges, net of credits, of $0.14 per diluted share
Adjusted diluted earnings per share, excluding charges and credits, was $0.05
Includes expense resulting from increased liability to joint venture partners of $0.12 per diluted share
Regulatory News:
Summary Financial Statements Fourth Quarter 2020
Reconciliation of U.S. GAAP to non-GAAP financial measures are below and in financial schedules.
Three Months Ended
December 31,
$(0.09)
$0.05
(11.8%)
Total Company revenue in the fourth quarter was $3,426.1 million. Net loss attributable to TechnipFMC plc was $39.3 million, or $0.09 per diluted share. These results included after-tax charges and credits totaling $62.7 mill
Eisai increases the number of participants in Clarity AD study
STOCKHOLM, Feb. 3, 2021 /PRNewswire/ BioArctic AB s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have increased the participant target number by approximately 200 in the pivotal Phase 3 study, Clarity AD, of drug candidate lecanemab (BAN2401) for the treatment of early Alzheimer s disease. The decision was taken proactively to ensure a robust dataset and to mitigate the potential impact of patients who temporarily missed doses due to the COVID-19 pandemic. It was based on a collaborative consultation with the FDA and in accordance with FDA and EMA COVID-19 regulatory guidance. Eisai also confirmed that the screening of participants was completed in January and that time for data readout for Clarity AD remains unchanged and is still expected by September 2022.